{
  "id": "5a7357e63b9d13c708000001",
  "type": "yesno",
  "question": "Is there an RNAi drug being developed to treat amyloidosis?",
  "ideal_answer": "Yes, patisiran is an investigational RNA interference (RNAi) therapeutic in development for the treatment of hereditary ATTR (hATTR) amyloidosis.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/28893208"
  ],
  "snippets": [
    {
      "text": "Patisiran is an investigational RNA interference (RNAi) therapeutic in development for the treatment of hereditary ATTR (hATTR) amyloidosis, a progressive disease associated with significant disability, morbidity, and mortality.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28893208",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [],
  "exact_answer": "Yes"
}